Carcinoma Colon

1 clinical trials · Condition

Record	Firm	Date
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (NCT05104905)	Faron Pharmaceuticals Ltd	2021-10-07

Every clearance here is in the API, with alerts when new ones post.